Alert detail
FDA Approval: ELIQUIS (APIXABAN) — Type 3 - New Dosage Form
Policy ID: FDA-NDA220073Specialty: CardiologyAdded: 6/30/2026Effective: April 17, 2025federal register
What changed
Eliquis oral suspension approved; oral route confirms Part D pathway.
Who’s affected: Cardiology billing teams · Effective: April 17, 2025
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.